159 related articles for article (PubMed ID: 29411820)
1. Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors.
Zhou S; Li GB; Luo L; Zhong L; Chen K; Li H; Jiang XJ; Fu Q; Long X; Bao JK
Org Biomol Chem; 2018 Feb; 16(9):1489-1495. PubMed ID: 29411820
[TBL] [Abstract][Full Text] [Related]
2. Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.
Du T; Qu Y; Li J; Li H; Su L; Zhou Q; Yan M; Li C; Zhu Z; Liu B
Mol Cancer; 2014 May; 13():100. PubMed ID: 24885567
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN
Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607
[TBL] [Abstract][Full Text] [Related]
5. Structural insight into maternal embryonic leucine zipper kinase (MELK) conformation and inhibition toward structure-based drug design.
Canevari G; Re Depaolini S; Cucchi U; Bertrand JA; Casale E; Perrera C; Forte B; Carpinelli P; Felder ER
Biochemistry; 2013 Sep; 52(37):6380-7. PubMed ID: 23914841
[TBL] [Abstract][Full Text] [Related]
6. Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight.
Touré BB; Giraldes J; Smith T; Sprague ER; Wang Y; Mathieu S; Chen Z; Mishina Y; Feng Y; Yan-Neale Y; Shakya S; Chen D; Meyer M; Puleo D; Brazell JT; Straub C; Sage D; Wright K; Yuan Y; Chen X; Duca J; Kim S; Tian L; Martin E; Hurov K; Shao W
J Med Chem; 2016 May; 59(10):4711-23. PubMed ID: 27187609
[TBL] [Abstract][Full Text] [Related]
7. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
Mahasenan KV; Li C
J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
[TBL] [Abstract][Full Text] [Related]
8. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
[TBL] [Abstract][Full Text] [Related]
9. MELK Accelerates the Progression of Colorectal Cancer via Activating the FAK/Src Pathway.
Liu G; Zhan W; Guo W; Hu F; Qin J; Li R; Liao X
Biochem Genet; 2020 Oct; 58(5):771-782. PubMed ID: 32472210
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
[TBL] [Abstract][Full Text] [Related]
11. 5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors.
Boutard N; Sabiniarz A; Czerwińska K; Jarosz M; Cierpich A; Kolasińska E; Wiklik K; Gluza K; Commandeur C; Buda A; Stasiowska A; Bobowska A; Galek M; Fabritius CH; Bugaj M; Palacz E; Mazan A; Zarębski A; Krawczyńska K; Żurawska M; Zawadzki P; Milik M; Węgrzyn P; Dobrzańska M; Brzózka K; Kowalczyk P
Bioorg Med Chem Lett; 2019 Feb; 29(4):607-613. PubMed ID: 30626559
[TBL] [Abstract][Full Text] [Related]
12. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y
Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305
[TBL] [Abstract][Full Text] [Related]
13. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
14. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
15. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2016 Apr; 7(14):18171-82. PubMed ID: 26918358
[TBL] [Abstract][Full Text] [Related]
17. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
[TBL] [Abstract][Full Text] [Related]
19. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract][Full Text] [Related]
20. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]